

Provincial Health Services Authority

Definition(s)

- Chemotherapy Induced Peripheral Neuropathy (CIPN): injury, or degeneration of the peripheral nerve fibers (motor, sensory, autonomic) caused by certain neurotoxic systemic therapy agents. Symptoms usually start in the fingers and toes and spread proximally in a glove and stocking distribution.
- Neuropathic pain: nerve pain initiated by damaged nerves, often described as sharp, tingling, burning, cold, and/or a pins and needles
- Allodynia: pain caused by a stimulus that does not normally cause pain (e.g. light touch, contact with clothing)
- Areflexia: absence of reflexes
- Dysesthesia: abnormal spontaneous sensations (burning, stinging, stabbing) from activities that do not normally cause pain }
- Paresthesia: an abnormal skin sensation in the absence of a stimulus (described as burning, prickling, itching, tingling)
- Glove and stocking syndrome: symmetrical manifestation of neuropathy in toes and fingers
- Hyperesthesia: increased sensitivity to sensory stimuli
- Hypoesthesia: decreased sensitivity to sensory stimuli
- Coasting Effect: when symptoms progress for months after treatment cessation
- **Carpal Tunnel Syndrome:** median nerve is compressed at the wrist, causing numbness, tingling, burning and pain in the affected hand and fingers


| FOCUSED HEALTH ASSESSMENT | | | | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|
| PHYSICAL ASSESSMENT | SYMPTOM ASSESSMENT | | | |
| Vital Signs Frequency as clinically indicated Assess patient for orthostatic hypotension and heart rate Observe Patient General Appearance: Observe gait as patient walks - note any hesitation, stumbling, unsteadiness, | *Consider <u>contributing factors</u> Normal Do you have any pre-existing peripheral neuropathy? Onset When did the symptoms begin? Provoking / Palliating | | | |
| holding onto walls Observe for any involuntary movements, tremors, spasms, wrist or foot drop Observe any difficulty with closing buttons, shaky handwriting, holding objects, keyboard use | What brings it on? What makes it worse? Better? Does it get better in between treatment? Quality (in last 24 hours) Can you describe symptoms? Sensory: numbness, tingling, pain, or burning Motor: falls, tripping, muscle weakness, abnormal gait, or paralysis, fine motor changes Autonomic: constipation, urinary dysfunction, sexual dysfunction, orthostatic hypotension Are symptom(s) intermittent or constant? | | | |
| | Region / Radiation Where are you experiencing your symptoms? (e.g. toes, fingers, symmetrical) Severity / Other Symptoms How bothersome is this symptom to you? (on a scale of 0 – 10, -with 0 not at all and 10 being the worst imaginable) Are there any accompanying symptoms? (e.g. pain) Treatment What medications or other strategies are you using right now?- How effective? Side effects? What medications or strategies have been effective in the past? | | | |

| Understanding / Impact on You Do your symptoms affect your role function, mood or ability to do activities of daily living? (e.g. buttoning shirt, writing, pick up small items)? Do your symptoms affect your ability to sleep (insomnia)? |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Value What do you believe is causing this problem? What is your comfort goal or acceptable level for this symptom (0 – 10 scale)? |

| PERIPHERAL NEUROPATHY GRADING SCALE(S) | | | | | |
|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|--|
| | | Adapted NCI CTCAE | (Version 4.03) | | |
| NORMAL | GRADE 1 | GRADE 2 | GRADE 3 | GRADE 4 | |
| | (Mild) | (Moderate) | <u>(Severe)</u> | (Life - threatening) | |
| | | Motor Gr | ade | | |
| Normal | NormalAsymptomatic; clinical or diagnosticModerate symptoms; limiting instrumental activities of daily living observations only; intervention not indicatedModerate symptoms; limiting instrumental activities of daily living meals, shopping, managing money)Severe symptoms; limiting self-care ADLs (e.g. bathing, dressing, feeding self, using the toilet, taking medications) ; assistive device indicated | | | | |
| | | Sensory G | Grade | | |
| Normal | Asymptomatic; loss of deep tendon reflexes or paresthesia | Moderate symptoms; limiting IADLs (e.g. preparing meals, shopping, managing money) | Severe symptoms; limiting self-care ADLs (e.g. bathing, dressing, feeding self, using the toilet, taking medications) | Life – threatening, consequences; urgent intervention indicated | |
| | | PAIN GRADIN | G SCALE | | |
| | | | | | |
| No pain | Mild pain | Moderate pain; limiting (IADLs) (e.g. preparing meals, shopping, managing money) | Severe pain, limiting self <u></u> care, ADLs -(e.g. bathing, dressing, feeding self, using the toilet, taking medications) | | |

*Step-Up Approach to Symptom Management:

Interventions Should be Based on Current Grade Level and Include Lower Level Grade Interventions as Appropriate



| | If on active chemotherapy treatment, may require treatment delays or reductions until symptoms resolve. Refer to specific chemotherapy protocols for direction: |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | http://www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy- protocols |
| Prevention of Thermal Injury | Avoid exposure of fingers and toes to very hot or very cold temperatures Avoid ice packs or heating pads. Ensure water temperature in shower or tub is less than 43 °C Use gloves when washing dishes or gardening, potholders when cooking Reinforce principles of hand and foot care, including daily visual inspection for sores or blisters For patients receiving Oxaliplatin: Sensory symptoms exacerbated by cold Wear gloves, socks and scarf to protect against cold temperatures Avoid eating cold food or drinks for few days after treatment |
| Fall Prevention | Clear walkways of clutter, turn on lights when entering a room Use skid free shower/ bathroom mats Remove throw rugs or other objects that could cause falls If gait unsteady, use assistive device (e.g. cane, walker) Avoid going barefoot or using loose, or tight_fitting shoes |
| Exercise/Activity | Passive range of motion exercises - may enhance reinnervation of denervated muscles Resistance exercises - can help strengthen muscles weakened by neuropathy Refrain from activities that require precise handwork (e.g. operating power tools or needlework) until symptoms lessen |
| Autonomic Symptoms | Orthostatic hypotension Dangle legs prior to getting up, hold onto secure surfaces when getting up and change positions slowly Constipation (See Resources & Referrals) Adequate daily fluid intake & high fibre diet Urinary retention Adequate daily fluid intake, bladder re-training exercises, empty bladder at same time every day Sexual dysfunction Consider- pharmacological intervention e.g. Viagra |
| Non- Pharmacological Management | Complementary Alternative Medicine (CAM) therapy may be helpful for some individuals Relaxation techniques, deep-breathing, meditation-, yoga, visual or guided imagery Neurofeedback – cognitive therapy Massage, Acupuncture, Transcutaneous electrical nerve stimulation(TENS) Cryotherapy for weekly paclitaxel eg, by using frozen socks and gloves before, during, and after drug infusion) may be useful to diminish objective and subjective symptoms of CIPN |
| Pharmacological Management | In collaboration with physician and pharmacist the following may be prescribed: Mild to moderate neuropathic pain and accompanying symptoms Acetaminophen, or NSAIDs Serotonin -norepinephrine reuptake inhibitor (SNRI) (eg. Duloxetine) Anticonvulsants (e.g. gabapentin or pregabalin), or tricyclic antidepressants (e.g. amitriptyline, nortriptyline, imipramine) Topical analgesic agents (e.g. capsaicin, lidocaine cream) Compounded topical gels (baclofen/amitryptiline/ketamine) A stepped protocol for constipation |
| Patient Education and Follow-Up | All patients should receive information about: Specific neurotoxic effects that can be expected from their chemotherapy regimen Platinum-induced neuropathy can progress for several months after completion of chemotherapy Report signs and symptoms of PN (sensory, motor, autonomic) to health care provider as soon as they are first noticed Strategies around self-care and personal safety Follow-up: Instruct patient/family to call back if symptoms worsen or do not improve Arrange for nurse initiated telephone follow-up |

| - Physician follow – up in ambulatory care setting may be indicated |
|---------------------------------------------------------------------|
| |
| |
| |
| |

GRADE 2 - GRADE 3

| URGENT: Requires medical attention within 24 hours | | | |
|-------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| Patient Care and Assessment | Collaborate with physician: If patient on Immunotherapy To rule out other causes or concomitant causes of peripheral neuropathy or need for further assessment in outpatient setting (r/o spinal cord compression). Facilitate arrangements as necessary. Lab tests may be ordered: e.g. vitamin B12 level, thyroid testing, fasting blood sugar or HGa1c, folate level If on active chemotherapy treatment, may require treatment delays or reductions until symptoms resolve. Refer to specific chemotherapy protocols for direction: http://www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols | | |
| Pharmacological Management | In collaboration with physician and pharmacist the following may be prescribed: Increased titration of dosages of anticonvulsant such as gabapentin, or tricyclic antidepressant such as nortriptyline (equal first-line). SNRIs such as duloxetine are third-line options Opioid (short or long acting) Corticosteroid (Refer to protocol specific algorithm if patient is on Immunotherapy) Methadone Mexiletine, Lidocaine infusion, Ketamine Compounded Topical Gel (baclofen/amitriptyline/ketamine) Medical Cannabinoids | | |

GRADE 4 OR

Signs of Spinal Cord Compression (e.g. back pain, motor weakness/loss, autonomic dysfunction)

| EMERGENT: Requires IMMEDIATE medical attention | | | |
|---------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|
| Patient Assessment and Care | If patient at home, instruct patient or family to call 911 or go to closest EMERGENCY ROOM Notify physician of nursing assessment and facilitate arrangements as necessary If patient on Immunotherapy, remind patient to present Immunotherapy alert card <u>Immunotherapy alert card</u> Notify physician if on active chemotherapy treatment, will require treatment delays until symptoms resolve or discontinuation. Refer to specific chemotherapy protocols for direction: | | |

| <u>http://www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols</u> Monitor vital signs and assess for other complications (available to internal BC Cancer staff) |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <u>Spinal cord compression alert guidelines</u> |

Ļ

| | RESOURCES & REFFERALS |
|----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Possible Referrals | Telephone Care for follow-up Physiotherapist Occupational Therapist Massage therapist Acupuncturist Patient and Family Counseling Pain and Symptom Management/Palliative Care (PSMPC) (if interfering with ADLs and if pt willing to try pharmacological management)- Home Health Nursing Neurologist – referral for nerve conduction studies, electromyography Sexual Health Clinic – referral for autonomic symptoms affecting sexual health |
| Immunotherapy Related Online Resources | Immunotherapy Alert Card Please refer to protocol specific algorithms to guide management of immune mediated side effects. E.g. Fair Pharmacare; BC Palliative Benefits. Can be found in "Other Sources of Drug Funding Section" Sleep-Wake Disturbances SMG <u>http://www.bccancer.bc.ca/nursing-site/Documents/17.%20Sleep-Wake%20Disturbance.pdf</u> Constipation SMG <u>http://www.bccancer.bc.ca/nursing-site/Documents/3.%20Constipation.pdf http://www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy/drug-funding</u> Patient Handout – "Nerve Damage" - <u>http://www.bccancer.bc.ca/health-info/coping-with-cancer/managing-symptoms-side-effects/nerve-damage</u> |
| Bibliography List | <u>http://www.bccancer.bc.ca/health-professionals/clinical-resources/nursing/symptom-</u> management |

| Contributing Factors | |
|--------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Chemotherapy Agents | High dose, high cumulative doses, or concurrent neurotoxic chemotherapy increases risk Platinum drugs, Vinca Alkaloids, Taxanes, Cytarabine, Interferon, Thalidomide, Bortezomib Appendix A: Chemotherapy Induced Neurotoxicity below |
| Other Systemic Therapy Agents | Immunotherapy – checkpoint inhibitors (bortezomib), antiangiogenic agents (Thalidomide, Pomalidomite, Lenalidomide Biologic Agents – brentuximab Hormonal Therapy – anastrozole |
| Other | Peripheral neuropathy from pre-existing condition may develop into a more severe or persistent CIPN (e.g. alcoholism, Vitamin B deficiency, diabetes, HIV, congenital neuropathy, hypothyroidism, connective tissue diseases, toxic neuropathy, post-herpetic neuralgia) Tumor infiltration & compression of spinal nerves Paraneoplastic syndromes (cytokines excreted from tumor cells) Radiation therapy involving the spine Surgical trauma Genetic Predisposition – variations in genetic makeup may contribute to risk of developing CIPN |
| Consequences | |
| cutaneous sensation:Motor symptom | pms : Dys/paresthesia, numbness and hypersensitivity, hypo/areflexia, pain, diminished vibratory or s s: Weakness, gait and/or balance disturbance, difficulty with fine motor skills, wrist or foot drop ptoms : Constipation, urinary dysfunction, sexual dysfunction, orthostatic hypotension |

- Quality of life exacerbation of other symptoms (e.g. pain, fatigue, depression, insomnia)
- Interference with ADLs and IADLs, compromised role function at home & work (may need gradual return to work-)
- Chemotherapy dose delays, reductions, discontinuation of treatment
- Patient safety risk for falls, tripping, burns, frostbite
- · Coasting effect symptoms may progress and become chronic even after treatment cessation

Appendix A: Chemotherapy Induced Neurotoxicity

(Table adapted from Up-to-date 2018 table: Neurotoxicity Associated with Cytotoxic Chemotherapy Agents)

| Drug | Sensory | Motor | Autonomic | Recovery | | |
|-------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------|--|--|
| Platinum Compou | Platinum Compounds | | | | | |
| Cisplatin and Oxaliplatin (Chronic toxicity) | Distal, symmetric sensory loss Painful paresthesias or numbness | Normal | Rare | May progress for few months once drug discontinued | | |
| Carboplatin | Similar to Cisplatin but less severe | Normal | Rare | Similar to Cisplatin | | |
| Oxaliplatin (Acute neurotoxicity) | Paresthesias and dysthesias in hands, feet and perioral area; often induced or worsened by cold | Cramps, jaw tightness, and spasms in throat muscles | None | Often resolves within 1 week | | |
| Vinca Alkaloids | • | | | | | |
| Vincristine Vinblastine Vinorelbine | Distal sensory loss in lower extremities | Less common; distal, symmetric weakness in lower limbs, may progress to foot drop | Constipation common with Vincristine Orthostatic hypotension less common | Often resolves within 3 months; can persist with Vincristine | | |

| Taxanes | | | | |
|---------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------|
| Paclitaxel Docetaxel | Mild, distal sensory loss (greater in feet than hands) Painful paresthesias | Occasional mild weakness in feet | Rare | Often resolves within 3 months; can persist |
| Other | •` | | | • |
| Bortezomib | Mild-mod distal symmetric sensory loss in lower extremities Painful paresthesia | Occasional mild distal weakness in lower limbs | Occasional, including orthostatic hypotension, diarrhea and constipation | Often resolves within 3 months; can persist |
| Thalidomide Pomalidomide Lenalidomide | Mild-mod distal symmetric sensory loss | Weakness, tremor, muscle cramps, fasciculation's are common | Constipation | Can persist for more than 1 yr |
| Brentuximab | Predominantly sensory | Rare | Rare | Often resolves in 3 months after treatment cessation, but may persist |
| Anastrozole | Carpal Tunnel Syndrome | Occasional weakness in affected limb | Normal | -May persist after treatment cessation |

Date of Print:

Revised: September, 2018 Created: January, 2010

Contributing Authors:

Revised by: Jen Pesut, RN BScN

Created by: Vanessa Buduhan, RN MN; Rosemary Cashman, RN MSc(A), MA (ACNP); Elizabeth Cooper, RN BScN, CON(c); Karen Levy, RN MSN; Colleen Sherriff, RN; Ann Syme RN Phd(C)

Reviewed by: Dr. Pippa Hawley, Palliative Medicine Specialist, Pain & Symptom Management (2019)